Page 6 - Rating Scale News Today

Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and...

FDA approves Dupixent (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis Dupixent is the first and only biologic medicine approved

Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and...

 FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis Dupixent is...

Tegoprubart was well-tolerated, with no drug-related serious adverse eventsDose dependent target engagement was demonstrated, and ALS associated pro-inflammatory biomarkers were both observed and... | May 31, 2022

Data show safety and efficacy of agent when paired with first-line antidepressants

Eledon Pharmaceuticals, Inc. (NASDAQ:NASDAQ:ELDN) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Paul Little – Chief Financial Officer David-Alexandre Gros –...

The FDA has approved Radicava ORS (edaravone) oral suspension for the treatment of adults with amyotrophic lateral sclerosis.

Study finds that low-dose medications for ADHD are not associated with changes in thyroid or growth hormone levels among children aged 6 to 12 years.

Study finds that low-dose medications for ADHD are not associated with changes in thyroid or growth hormone levels among children aged 6 to 12 years.